| Species |
Human |
| Protein Construction |
IL-37 (Lys27-Asp192)
Accession # Q9NZH6-2 |
|
| Purity |
> 95% as determined by BisTris PAGE
> 95% as determined by HPLC |
| Endotoxin Level |
Less than 1EU per μg by the LAL method. |
| Biological Activity |
Human IL18BP, hFc Tag captured on CM5 Chip via Protein A can bind IL-37, Human in SPR assay (Biacore T200). Test result was comparable to standard batch. |
| Expression System |
E.coli |
| Theoretical Molecular Weight |
18.55 kDa |
| Apparent Molecular Weight |
The protein has a predicted MW of 18.55 kDa same as Bis-Tris PAGE result. |
| Formulation |
Lyophilized from 0.22μm filtered solution in 20mM PBS, 2mM DTT (pH 7.4). |
| Reconstitution |
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. |
| Storage & Stability |
Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
| Target Background |
IL-37 is a unique member of the IL-1 family of cytokines, which functions as a natural suppressor of inflammatory and immune responses. Immune and non-immune cells produce IL-37 precursor following pro-inflammatory stimuli. Following activating cleavage by caspase-1, mature IL-37 translocates to the nucleus, where it suppresses transcription of pro-inflammatory genes. |
| Synonyms |
FIL1 zeta; IL-1X; IL-1F7; IL-1H; IL-1H4; IL-1 zeta; IL-1RP1; FIL1Z; IL1F7; IL1H4; IL1RP1 |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
